Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04160390 · ClinicalTrials.gov registry record
Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant
A clinical trial of Malignant Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient, sponsored by City of Hope Medical Center.
- Active
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT04160390: Active study of Malignant Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient, sponsored by City of Hope Medical Center.
NCT04160390 is a study of Malignant Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 72 participants, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04160390, a study of Malignant Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be used to predict how well patients will process and respond to cyclophosphamide.
Primary Outcome
Will determine whether readily available patient characteristics influence CY PK using population (pop)PK modeling. Will validate our existing popPK model of CY, 4HCY, and carboxyethylphosphoramide mustard.
Conditions Studied
Interventions
- OTHER Biospecimen Collection-Blood
- OTHER Biospecimen Collection-Stool
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2027-04-24 |
What the registry record for NCT04160390 still lists
NCT04160390 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection-Blood is the first listed.
NCT04160390 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04160390 about?
NCT04160390 is a clinical study titled "Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant". This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be use...
What is the current status of trial NCT04160390?
This trial is currently active not recruiting. The enrollment target is 72 participants. The study started on 2018-11-13. Estimated completion is 2027-04-24.
What conditions does trial NCT04160390 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor.
What interventions are being tested in trial NCT04160390?
The interventions under investigation include: Biospecimen Collection-Blood (OTHER), Biospecimen Collection-Stool (OTHER).
Who is sponsoring clinical trial NCT04160390?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04160390 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04160390's enrollment target sits among peer trials
72 39th of 59 higher than 21 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI